TY  - JOUR
TT  - Cost-effectiveness analysis of type 2 diabetes in outpatient therapy in Turkey
AU  - Toprak, İlkim Deniz
AU  - Yürüyen, Gülden
AU  - Özgün Çil, Eylem
AU  - Arman, Yücel
AU  - Demir, Pınar
AU  - Çakmak, Ramazan
AU  - Akcan, Tuğçe
AU  - Özcan, Mustafa
AU  - Akarsu, Murat
AU  - Altun, Özgür
AU  - Aydın Yoldemir, Şengül
AU  - Kırna, Kerem
AU  - Tükek, Tufan
PY  - 2017
DA  - September
DO  - 10.18017/iuitfd.363564
JF  - Journal of Istanbul Faculty of Medicine
JO  - İst Tıp Fak Derg
PB  - İstanbul Üniversitesi
WT  - DergiPark
SN  - 1305-6441
SP  - 92
EP  - 97
VL  - 80
IS  - 3
KW  - Tip 2 diabetes mellitus; maliyet etkinlik; tıbbi bakım maliyeti
N2  - Objective: The purpose of this study is toestimate the cost-effectiveness of screening, treatment, and examination ofpatients with type 2 diabetes during a yearly period and expose its importancein diabetes control.Materials and Methods: Five hundredpatients with type 2 diabetes who had received outpatient therapy in the pastyear were enrolled in the study. Patients were divided into three categoriesaccording to their hemoglobin A1c (HbA1c) (%) levels: good control (HbA1c<7%), fair control (HbA1c 7%–10%), and poor control (HbA1c >10%). Averageannual costs of treatment, examination, and laboratory workup were compared forthe three groups.Results: The average annual cost ofmedication for 500 type 2 diabetes patients was $556.50, while the cost ofscreening and examination was $89.20 per patient. The average yearly treatmentcost per patient was $287.90 for patients with HbA1c ≤7%, $647.90 for patientswith HbA1c 7%–10%, and $752.40 patients with HbA1c ≥10%. The average annualcosts of treatment with only oral anti-diabetic drugs (OAD), insulin only, andboth OAD and insulin were $154.80, $837.50, and $819.30, respectively.Conclusion: While the cost to treatdiabetic patients with good control was significantly lower than the treatmentcost of patients with poor control, there was no significant difference inlaboratory workup and examination costs. When patients treated with OAD only,insulin only and OAD + insulin were compared, treatment costs for the OAD onlygroup were significantly lower than the costs to treat the insulin only and OAD+ insulin groups. No correlation between age or sex and medication cost werefound. However, a strong correlation was found between diabetes duration andtreatment cost.
CR  - 1.	King H, Rewers M. Global estimates for prevalence of diabetes mellitus and imparied glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993;16(1):157-77.
CR  - 2.	Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Diabetes Atlas- Global health care expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(3):293-301.
CR  - 3.	Jönsson B. Revealing the cost of Type 2 diabetes in Europe. Diabetologia 2002;45(7):S5-12.
CR  - 4.	Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, et al. TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28(2):169-80.
CR  - 5.	International Diabetes Federation, Diabetes Atlas, İnternational Diabetes Federation, Brussels, 3rd ed., 2006.
CR  - 6.	Malhan S, Öksüz E, Babineaux MS, Ertekin A, Palmer PJ. Assessment of the direct medical costs of the type 2 diabetes mellitus and its complications in Turkey. Turk J Endocrinol Metab  2014;18(2):39-43.
UR  - https://doi.org/10.18017/iuitfd.363564
L1  - https://dergipark.org.tr/tr/download/article-file/378588
ER  -